Table 4.
Pooled temporal analyses of numerical overall and progression-free survival.
| Disease/ overall survival | No. of studies | No. of patients | Pooled results, LCT vs. control (95% confidence interval) |
|---|---|---|---|
| Overall survival | |||
| NSCLC | |||
| 1-year OS | 11 | 1112 | 85.0% (75.8–91.1) vs. 69.4 (54.4–81.1) |
| 2-year OS | 10 | 960 | 65.2% (55.5–73.7) vs. 37.0 (26.7–48.6) |
| Colorectal | |||
| 1-year OS | 3 | 602 | 88.1% (57.0–97.7) vs. 67.5% (37.7–87.7) |
| 2-year OS | 3 | 602 | 66.2% (22.4–93.0) vs. 33.2% (8.8–71.9) |
| Prostate | |||
| 3-year OS | 2 | 1477 | 95.6% (47.1–99.8) vs. 92.6% (41.9–99.5) |
| SCLC | |||
| 1-year OS | 2 | 130 | 60.7% (38.1–79.4) vs. 42.8 (14.7–76.4) |
| Progression-free survival | |||
| NSCLC | |||
| 1-year PFS | 8 | 891 | 61.3% (48.7–72.6) vs. 35.7% (23.9–49.6) |
| 2-year PFS | 5 | 636 | 28.9% (16.8–45.0) vs. 8.6% (5–14.5) |
| Colorectal | |||
| 1-year PFS | 2 | 372 | 60.2% (50.2–69.4) vs. 29.5% (14.2–51.4) |
| 2-year PFS | 2 | 372 | 35.7% (26.9–45.6) vs. 10.5% (2.5–34.7) |
| Prostate | |||
| 1-year PFS | 5 | 1095 | 82.7% (70.6–90.5) vs. 71.3% (44.3–88.5) |
| 2-year PFS | 5 | 1095 | 61.7% (42.8–77.6) vs. 45.9% (24.7–68.6) |
| SCLC | |||
| 1-year PFS | 2 | 130 | 30.9% (17.2–49.2) vs. 16.6% (8.0–31.3) |
LCT local consolidative treatment, NSCLC non-small cell lung cancer, OS overall survival, HCC hepatocellular carcinoma, SCLC small cell lung cancer, PFS progression-free survival.